Abcam, ab263247, Human LRRC59 knockout HEK-293T cell lysate

Size: 1Kit
LRRC59 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LRRC59, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein LRRC59 also known as Leucine-Rich Repeat-Containing Protein 59 is involved in several cellular processes. This protein has a molecular mass of approximately 40 kDa and is expressed in various tissues including the liver kidney and brain. LRRC59 contains multiple leucine-rich repeats which are structural motifs contributing to protein-protein interactions. These interactions are important for the protein's function within the cell.
Biological function summary
LRRC59 is involved in nuclear import pathways and acts as an anchor for certain proteins that need to be translocated into the nucleus. It interacts with the importin-family proteins to facilitate the transport of proteins with nuclear localization signals. LRRC59 works as a part of a larger protein complex which includes importin and nucleoporins to control transport into the nucleus. This positioning suggests that LRRC59 has an active role in regulating gene expression by controlling the nuclear entry of transcription factors and other nuclear proteins.
Pathways
LRRC59 plays a part in cellular transport and signaling pathways. It integrates into the nuclear transport pathway directly influencing gene expression by ensuring the proper nuclear import of signaling molecules. In particular it influences the well-known MAPK signaling pathway through interactions with other proteins like importin-β. These associations emphasize LRRC59’s role in maintaining cellular homeostasis and its potential impact on several signaling cascades.
LRRC59 has been linked to specific cancers and certain neurodegenerative conditions. Abnormal expression of LRRC59 has been observed in some cancer types suggesting a role in tumor progression possibly through altered nuclear transport. Additionally LRRC59 is associated with Alzheimer's disease due to its interactions with proteins like tau which are involved in the pathological aggregation seen in this disorder. These connections highlight LRRC59 as a potential target for therapeutic interventions in these diseases.